Back to News Items

August 2012: New Article: Is Approval of Apixaban in the U.S. Near?

Main Bullet Points:

*Apixaban praised at the 2012 International Stroke Conference.

* The mortality rate of patients was higher for the group of participants who received aspirin as compared to those who were dosed with  apixaban.

* Apixaban (Eliquis) is an anticoagulant that is a direct factor Xa inhibitor, or a Vitamin K antagonist.

*In the U.S. alone, roughly 17,500 of the 795,000 strokes that occur annually are a result of atrial fibrillation.

* Already approved in Europe, Apixaban (Eliquis) is awaiting the final FDA approval in the United States.


Dun and Bradstreet